A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Extended-Release Paliperidone as Maintenance Treatment After an Acute Manic or Mixed Episode Associated With Bipolar I Disorder - R076477BIM3004

Janssen-Cilag International N.V.0 个研究点目标入组 685 人开始时间: 2006年9月1日最近更新: 2014年2月10日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方: Janssen-Cilag International N.V.
入组人数: 685

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•·Man or woman, between 18 (or the minimum age to provide informed consent in the jurisdiction in which the study is taking place, whichever is older) and 65 years of age, inclusive
•·Signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study. NOTE: It is acceptable to have additional signatures if required by local regulations.
•·Subjects must have signed the informed consent form for genetic research indicating whether they do or do not agree to participate in the genetic component of the study (where local regulations permit). NOTE: Participation in the genetic testing component is not required for participation in the study.
•·Meet DSM-IV criteria for Bipolar I Disorder, Most Recent Episode Manic or Mixed (with or without psychotic features) at the time of screening (Days -7 to -1). Subjects with other Axis I and II disorders, except those listed in the exclusion criteria, are also acceptable. All diagnoses will be confirmed by the MINI.
•·History of at least 2 previously documented mood episodes associated with Bipolar I Disorder (1 of which must be a manic or mixed episode) that required medical treatment within the 3 years before screening.
•·Total score of at least 20 on the YMRS at screening and at baseline (Day 1).
•·Women must be postmenopausal for at least 1 year, surgically sterile, abstinent, or agree to practice an effective method of birth control if they are sexually active before entry and throughout the study (effective methods of birth control include prescription hormonal contraceptives, contraceptive injections, intrauterine devices, double barrier method, contraceptive patch, and male partner sterilization). Female subjects must also have a negative urine pregnancy test at screening and baseline (Day 1).
•·Able and willing to comply with self-administration of study drug, or have consistent help or support available.
•·Able to meet study requirements (e.g., answer self-administered questionnaires). NOTE: If a subject is unable to read study information or answer study questions, study personnel may read the questions to the subject and the subject may then mark his or her choice.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

排除标准

•Potential subjects who meet any of the following criteria will be excluded from the participation in the study:
•- Meet DSM-IV criteria for any type of episode associated with bipolar disorder other than Bipolar I Disorder, Most Recent Episode Manic or Mixed (with or without psychotic features)
•- Meet DSM-IV criteria for rapid cycling
•- Meet DSM-IV criteria for schizoaffective disorder
•- Known or suspected borderline or antisocial personality disorder
•- In the opinion of the investigator, are at significant immediate risk for suicidal or violent behaviour during the course of the study based on current status or prior history (e.g., suicide attempts during previous episodes)
•- Known or suspected history of substance dependence (excluding nicotine and caffeine) according to DSM-IV criteria, with DSM-IV duration criteria modified to at anytime within the previous 3 months
•- Serious or unstable medical illness (e.g., cardiovascular disease, neurologic, hematologic, renal, hepatic, immunologic, endocrine, or other systemic illness), or have a history of cerebrovascular disease or uncontrolled or insulin-dependent diabetes mellitus. Subjects with chronic illness may be included but must be stable and otherwise physically healthy on the basis of a physical examination, medical history, ECG, and the results of chemistry, hematology, and urinalysis testing.
•- Known or suspected seizure disorder or require treatment with anticonvulsants for another indication (e.g., migraine prophylaxis)
•- History of severe pre-existing gastrointestinal narrowing (pathologic or iatrogenic) or inability to swallow oral study drug whole with the aid of water
•- Results at screening or baseline (Day 1) for alanine aminotransferase or aspartate aminotransferase greater than twice the upper limit of the central laboratory's reference range. If the results for any other chemistry, hematology, or urinalysis testing are not within the central laboratory's reference ranges, the subject can be enrolled only if, in the opinion of the investigator, the deviations are not clinically significant.
•- Have active hypo- or hyperthyreoidism unless stabilized on appropriate medication for at least 3 months before the screening phase
•- History of neuroleptic malignant syndrome or similar encephalopathic syndrome
•- Have a moderate to severe degree of tardive dyskinesia at screening
•- Known or suspected history of hypersensitivity or intolerance to paliperidone, risperidone, or olanzapine, or suspected history of lifethreatening drug allergy or hypersensitivity to any drug
•- Have received benzodiazepines at dosages equivalent to 4 mg/day of lorazepam or higher for a period of 3 months or longer immediately before the screening phase
•- have received clozapine, aripiprazole, or fluoxetine within 1 month before the screening phase
•- Have received antidepressant therapy (other than fluoxetine) within 7 days (or 5 times the half-life of the product, whichever is longer) before study drug administration on Day 1. Antidepressant medications include known antidepressants used for other indications (e.g., anxiety disorders, sleep disturbance, and smoking cessation) as well as St. John's Wort, SAM-e, and other over-the-counter antidepressants.
•- Use of antiparkinsonian drugs or ß-adrenergic blockers (for any indication other than hypertension) within 3 days before study drug administration on Day 1
•- Have recently used cocaine, phencyclidine, amphetamine, methylphenidate, pemoline, an opioid (

研究者

发起方

Janssen-Cilag International N.V.

相似试验

进行中（未招募）

不适用

A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Flexibly-Dosed Extended-Release Paliperidone Compared with Flexibly-Dosed Quetiapine and Placebo in the Treatment of Acute Manic and Mixed Episodes Associated with Bipolar I Disorder - Protocol R076477-BIM-3002 Phase 3Bipolar I Disorder

EUCTR2005-005812-25-LTJanssen-Cilag International N.V.475

进行中（未招募）

1 期

EUCTR2005-005812-25-GRJanssen-Cilag International N.V.

进行中（未招募）

不适用

A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of CG5503 Immediate Release Formulation in the Treatment of Acute Pain From Total Hip Replacement Surgery Followed by a Voluntary Open-Label Extension. - n/a

EUCTR2006-004513-18-EEJohnson & Johnson Pharmaceutical Research & Development, L.L.C.1,100

进行中（未招募）

不适用

EUCTR2006-004513-18-GBJohnson & Johnson Pharmaceutical Research & Development, L.L.C.1,100

进行中（未招募）

不适用

EUCTR2006-004513-18-HUJohnson & Johnson Pharmaceutical Research & Development, L.L.C.1,100